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Patients with advanced chronic kidney disease are suitable for 
substitutive renal treatment to replace kidney function. Currently 
and according to the Epidemiological Study of Chronic Renal 
Failure in Spain (EPIRCE), there is a prevalence of 6.8% of 
chronic renal failure at stages 3 to 5 among Spain’s population 
(Otero, de Francisco, Gayoso, García, & EPIRCE study group, 
2010). There are three possible treatment modalities for the disease: 
hemodialysis, peritoneal dialysis, and transplant. Hemodialysis 
was the fi rst treatment designed for this purpose and it is currently 
the most extensively used technique in Spain. Peritoneal dialysis 
is an alternative to hemodialysis and is carried out in the patient’s 
home, and the patient is responsible for self-administering the 
treatment by means of a peritoneal catheter. 
Low adherence to medical treatment is a widely extended 
problem among chronically ill patients (Cvengros, Christensen, & 
Lawton, 2004). Although therapeutic compliance has been defi ned 
as the extent to which the patient’s’ behavior coincides with the 
healthcare professional’s instructions (Haynes, Taylor, & Sackett, 
1979), more recently, therapeutic adherence has been shown to be 
a complex and multidimensional behavior (Remor, 2011), which 
goes beyond the simple intake of prescribed medication. For 
example, in both its modalities, dialysis is a highly invasive non-
curing treatment, which should be accompanied by a specifi c diet, 
fl uid restriction, and a large number of daily pills, all of which 
involve a high cost for the patients and their families (Cukor, 
Cohen, Peterson, & Kimmel, 2007). Within this complex treatment 
regime, the prescription of oral phosphate binders is practically 
universal (Tonelli, Pannu, & Manns, 2010). The problem of 
phosphorus control is an arduous task for the medical professional 
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Abstract
Background: A low rate of adherence to treatment is a widespread 
problem of great clinical relevance among dialysis patients. The objective 
of the present study is to determine the relationship between adherence, 
emotional state (depression, anxiety, and perceived stress), and health-
related quality of life (HRQOL) in renal patients undergoing dialysis. 
Method: Two patient groups (30 in hemodialysis and 31 in peritoneal 
dialysis) participated in this study. We evaluated aspects of adherence, 
depression, anxiety, perceived stress, and HRQOL with self-report and 
standardized instruments. Results: Peritoneal dialysis patients reported 
signifi cantly higher levels of adherence to treatment and better HRQOL in 
Physical Function and Bodily Pain domains. Depression level is associated 
with HRQOL indicators. We did not fi nd any differences regarding 
specifi c adherence to antihypertensive and phosphate binder drugs or in 
psychological variables depending on the modality of dialysis. Patients 
with adherence to antihypertensive drugs show better physical HRQOL. 
The predictors of HRQOL in dialysis patients were: work, gender and 
depression. Conclusions: Our results suggest that the modality of dialysis 
does not differentially affect the emotional state or specifi c adherence to 
drugs, but it is nevertheless related to their overall adherence to treatment 
and to their HRQOL.
Keywords: adherence, anxiety, depression, quality of life, dialysis.
Resumen
Adhesión al tratamiento, estado emocional y calidad de vida en 
pacientes con insufi ciencia renal crónica en tratamiento con diálisis. 
Antecedentes: la escasa adhesión al tratamiento y un estado psicológico 
negativo constituyen potenciales factores de riesgo para la calidad de vida 
relacionada con la salud (CVRS) de los pacientes en diálisis. El objetivo 
del presente trabajo fue estudiar las relaciones entre adhesión, estado 
emocional (depresión, ansiedad y estrés percibido) y CVRS en pacientes 
en hemodiálisis y diálisis peritoneal. Método: participaron dos grupos 
de pacientes (30 en hemodiálisis y 31 en diálisis peritoneal). Evaluación 
mediante autoinformes e instrumentos estandarizados. Resultados: los 
pacientes en diálisis peritoneal informaron de niveles signifi cativamente 
más altos de adhesión y mejor CVRS en función física y dolor corporal. 
La depresión se relaciona de manera signifi cativa con la CVRS. No 
encontramos diferencias en adhesión específi ca a fármacos hipotensores 
y quelantes del fósforo ni en las variables psicológicas en función de la 
modalidad de diálisis. Al analizar la muestra en conjunto los pacientes 
adherentes a los hipotensores tienen mejor CVRS física. Los predictores 
de CVRS en pacientes en diálisis fueron: trabajo, género y depresión. 
Conclusiones: nuestros resultados sugieren que la modalidad de diálisis 
no afecta al estado emocional ni a la adhesión específi ca a fármacos, pero sí 
está asociada al grado de adhesión global al tratamiento y CVRS.
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and the patient, since it is one of the lesser known aspects of the 
treatment and one with the lowest rates of adherence (Arenas, 
Malek, Álvarez-Ude, Moledus, & Reig-Ferrer, 2010). Likewise, 
managing hypertension has classically been linked to the patient’s 
lack of adherence, both in the general population and in that with 
kidney disease (Moser & Setaro, 2006). Hence, management of 
both complications can be considered a challenge in the treatment 
of kidney disease, and it may be possible relevant indicators of 
non-adherence that should be studied in these patients.
Kidney patients present a decrease in their perception of health 
and an increase in anxious-depressive states (Abdel-Kader, Unruh, 
& Weisbord, 2009). Some of the causes that are attributed to this 
decrease in quality of life are associated with comorbidity, lack 
of professional occupation, and complex therapeutic regimes 
(Rodríguez-Fructuoso, Castro, Oliveira, Prata, & Morgado, 2011).
The current state of knowledge of the behavior of adherence, the 
emotional state, and quality of life of patients on hemodialysis and 
peritoneal dialysis has revealed the need to study these phenomena 
relatedly in order to describe dialytic technique that may be of 
greater benefi ts for the patient.
Considering the above-mentioned variables, we propose to 
describe the level of adherence to treatments, emotional state 
(depression, anxiety and perceived stress), as well as health-related 
quality of life (HRQOL) of patients on hemodialysis and peritoneal 
dialysis. We shall also determine whether there are differences in 
the variables assessed as a function of dialysis modalities, and the 
relations among the variables of the study. 
Method
Participants
Sixty-one patients on dialysis in a nephrology unit of a 
university hospital of the Region of Madrid were assessed for the 
present study. Details of the sociodemographic characteristics and 
health status of the sample are summarized in Tables 1 and 2.
Instruments
Survey of clinical profi le, sociodemographic data, and 
biochemical parameters. This survey collects data on age, months 
on dialysis, date of diagnosis, cause of kidney disease, Charlson 
comorbidity index, use of psychotropic drugs, daily number of 
pills, gender, civil status, work, educational level, potassium, 
calcium, phosphorus, hypertension, and hyperphosphoremia.
Survey of facilitators of general adherence to treatment 
(α= .67). We selected and adapted items from a prior measure 
of adherence to treatment (Remor, 2002). The survey gathers 
information on: the treatment, the relation with the healthcare 
team, family support, knowledge of medication and diet, self-
administration of medication, perceived benefi ts of medication 
and diet, patients’ following nephrologists’ instructions, perceived 
effort and perceived capacity to follow treatment.
Morisky-Green-Levine Test (Morisky, Green, & Levine, 1986). 
We used this 4-item test to measure adherence to oral treatment 
for hypertension and hyperphosphoremia. The Spanish version 
was validated by Val-Jiménez, Amorós, Martínez, Fernández, & 
León (1992). This instrument has been shown to be effective in the 
detection of noncompliant patients in chronic pathologies such as 
diabetes and hypertension (Roos, Pittman, & Koo, 2002). 
Beck Depression Inventory, version 2 (α= .90; BDI-II; Beck, 
Steer, & Brown, 1996). We used the Spanish version of Sanz, 
Perdigón, and Vázquez (2003). According to the original authors, 
scores of 17 or higher discriminate depressive episodes that require 
treatment with a reliability of 90%.
State-Trait Anxiety Inventory (α= .59; STAI, Spielberger, 
Gorsuch, & Lushene, 1983). We used the Spanish version of 
Seisdedos (1982). For the present study, we selected the State Anxiety 
subscale (STAI-S). The data refl ected on the scale are of a transitory 
nature, that is, they should be considered a representative sample of 
the subject’s anxiety response only at the moment of administering 
the test. Higher scores indicate a greater state-anxiety.
Perceived Stress Scale, 10-item version (α= .88; PSS-10, Cohen, 
Kamarck, & Mermelstein, 1983). We used the Spanish version of 
Remor (2006). This tool assesses the stress perceived during the 
past month. Higher scores correspond to more perceived stress.
Short-form Health Survey (MOS SF-36, McHormey, Ware, & 
Raczeck, 1993). We used the Spanish version of Alonso, Prieto, 
and Antó (1995). This survey assesses 8 dimensions of physical and 
mental health status: Physical Function (α= .90), Physical Role (α= 
.97), Bodily Pain (α= .93), General Health (α= .65), Vitality (α= 
.83), Social Function (α= .79), Emotional Role (α= .94), and Mental 
Health (α= .78). There are two component summaries: physical 
(PCS) and mental (MCS). Higher scores indicate greater HRQOL.
Procedure 
Approval from the Clinical Research Ethics Committee of the 
hospital was obtained before beginning the study. The nephrology 
unit attends 110 patients on dialysis. Fifty-fi ve of them received 
treatment in the hemodialysis unit, and the rest in the peritoneal 
dialysis unit. During the months of April and May of 2010, all the 
patients who met the inclusion criteria (18 years or older, more than 
3 months in the dialysis program, no diagnosed psychiatric disease, 
ability to understand the assessment protocol and having signed the 
informed consent) were offered the possibility to participate in this 
study. Of the patients who met the inclusion criteria (n= 63), two 
refused to participate due to lack of time. Sixty-one patients (55% of 
the total patients in the unit) accepted and were assessed by a trained 
psychologist when they came for their medical examination.
Data analysis
The statistical analyses were performed with the SPSS 17.0 
program. To compare quantitative variables in the two groups, we 
used Student’s t for independent variables as the parametric test 
and the Mann-Whitney U as the nonparametric test. The qualitative 
variables were compared by means of chi-square. The relation 
between the variables was explored with Spearman and Pearson 
correlation coeffi cients. To determine which variables contributed 
to the prediction of the physical and mental component summaries 
of HRQOL, we used stepwise multiple linear regression analysis. 
In all the analyses, we used 95% confi dence intervals. 
Results
Clinical profi le, sociodemographic data and biochemical parameters 
 
Of all the patients on hemodialysis and peritoneal dialysis, 
56.6 and 87.0%, respectively, were in oral treatment with 
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antihypertensive drugs, and 83.3 and 83.8%, respectively, were in 
oral treatment with phosphate binders. The Charlson comorbidity 
index was signifi cantly higher in patients on hemodialysis (p= 
.000). The patients in peritoneal dialysis were signifi cantly 
younger (p= .003), they were occupationally active (p= .003), and 
they had a higher educational level (p= .005) than the patients on 
hemodialysis (see Table 1).
Adherence profi le, psychological variables, and HRQOL
 
As shown in Table 2, patients on peritoneal dialysis reported 
higher general adherence to treatment (p= .004), they were better 
informed (p= .000), and they perceived a better relationship with the 
healthcare team (p= .000). In contrast, the patients on hemodialysis 
reported having greater knowledge of the recommended diet than 
patients on peritoneal dialysis (p= .000). In both dialysis modalities, 
we observed high rates of nonadherence to antihypertensive drugs 
(90.9% on hemodialysis and 82.8% on peritoneal dialysis) and to 
phosphate binders (68.4% on hemodialysis and 85.2% on peritoneal 
dialysis). No group differences in adherence as measured by the 
Morisky-Green-Levine Test, or in the psychological variables 
were observed. In the analysis of the HRQOL dimensions, patients 
in peritoneal dialysis presented better Physical Function (p= .007) 
and less Bodily Pain (p= .023), as well as a higher PCS (p= .030). 
Taking into account the gender variable, we observed differences 
in the following HRQOL dimensions in favor of the men: Physical 
Function (men: M= 66.19, SD= 23.9;, women: M= 41.38, SD= 
26.94, t= 3.544, p= .001); Physical Role (men: (M= 61.75, 
Table 1
Clinical profi le, sociodemographic data and biochemical parameters in the two dialysis modalities
                        Total sample (N= 61)  HD (N= 30)                       DP (N= 31)
Variables Mean (SD) Range N (%) Mean (SD) Range N (%) Mean (SD) Range N (%) Statistic p
Age
Months on dialysis 
Charlson
Date of CRD diagnosis
<6 years
6-10 years
>10 years
Cause of kidney disease
Diabetes Mellitus
Other
Current psychotropic drugs
Yes
No
Number of daily pills
0-10
>10
54.2 (17.36) 21-90
43.9 (61.68) 4-384
5.82 (3.15) 2-14
18 (29.5)
12 (19.7)
31 (50.8)
9 (14.8)
52 (85.2)
14 (23.0)
47 (77.0)
28 (47.5)
33 (52.5)
60.6 (16.66) 23-90
56.9 (81.73) 4-384
7.23 (3.11) 14-2
7 (23.3)
6 (20.0)
17 (56.7)
6 (20.0)
24 (80.0)
5 (16.7)
25 (83.3)
17 (58.6)
13 (42.4)
47.9 (15.86) 21-75
31.4 (28.64) 4-132
4.45 (2.55) 12-2
11 (35.5)
6 (19.4)
14 (45.2)
3 (9.7)
28 (90.3)
9 (29.0)
22 (71.0)
19 (36.7)
12 (63.3)
t= 3.06
t= 1.64
t= 3.88
χ²= 1.16
χ²= 1.29
χ²= 1.31
χ²= 2.85
.003
.106
.000
.559
.256
.251
.091
Sex
Male
Female 
Is living 
Alone
With someone else
Work
Yes
No
Educational level
Primary
Secondary
University studies 
43 (70.5)
18 (29.5)
22 (36.1)
39 (63.9)
14 (23.0)
47 (77.0)
24 (39.3)
14 (23.0)
23 (37.7)
18 (60.0)
12 (40.0)
10 (33.3)
20 (66.7)
2 (6.7)
28 (93.3)
18 (60.0)
4 (13.3)
8 (23.3)
25 (80.6)
6 (19.4)
12 (38.7)
19 (61.3)
12 (38.7)
19 (61.3)
6 (19.4)
10 (32.3)
15 (48.4)
χ²= 3.12
χ²= 0.19
χ²= 8.85
χ²= 0.68
.977
.662
.003
.005
Biochemical parameters
Potassium
Calcium
Phosphorus
Hypertension
Yes
No
Hyperphosphoremia
Yes
No 
4.57 (0.85) 3.10-6.90
9.22 (0.81) 7.30-11.30
4.37 (1.28) 1.80-8.40
44 (73.3)
17 (26.7)
51 (83.3)
10 (16.7)
5.07 (0.79) 3.40-6.90
9.24 (0.86) 7.30-11.30
4.21 (1.38) 1.80-7.20
17 (56.6)
13 (43.4)
25 (83.3)
5 (16.7)
4.09 (0.58) 3.10-5.30
9.21 (0.77) 7.30-10.40
4.54 (1.19) 2.80-8.40
27 (87.0)
4 (13.0)
26 (83.8)
5 (16.2)
t= 5.44
t= 0.14
t= 0.96
χ²= 8.52
χ²= 0.00
.000
.888
.341
.004
 
1
Note: HD= hemodialysis, PD= peritoneal dialysis, CRD= chronic renal disease, Charlson= modifi ed Charlson comorbidity index
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SD= 33.87; women: M= 37.50, SD= 30.01, t= 2.626, p= .011); 
Emotional Role (men: M= 87.69, SD= 23.07; women: M= 65.27, 
SD= 37.29, t= 2.842, p= .006); Mental Health (men: M= 61.58, 
SD= 9.77; women: M= 52.50, SD= 16.82, t= 2.611, p= .012); 
PCS (men: M= 60.58, SD= 8.06; women: M= 53.44, SD= 8.29, t= 
23.082, p= .003); MCS (men: M= 49.64, SD= 4.55; women: M= 
45.00, SD= 7.34, t= 2.927, p= .05).
Effects of depression on the indicators of adherence and of 
HRQOL 
Of the total sample, 23% presented some degree of depression 
suitable to treatment (BDI >17). As shown in Table 3, patients 
classifi ed as presenting clinical depression (BDI-II) reported 
power adherence to treatment (p= .010) and lower HRQOL in the 
Physical Function (p= .021), Physical Role (p= .002), Emotional 
Role (p= .000), and Mental Health (p= .020) subscales. PCS (p= 
.002) and MCS (p= .023) were also lower in depressed patients. 
No signifi cant relationship between specifi c markers of adherence 
(BP and HP Morisky-Green-Levine Test) and depression were 
found.
Associations between indicators of specifi c adherence to 
antihypertensive drugs and phosphate binders, psychological 
variables and HRQOL
 
The patients who reported adherence to antihypertensive 
drugs presented greater HRQOL in the Physical Role subscale 
(p= .018) and in the PCS (p= .046). In contrast, no statistically 
signifi cant differences were observed in any of the psychological 
variables. With regard to specifi c adherence to phosphate binders, 
no statistically signifi cant differences were observed between 
Table 2 
Adherence profi le, psychological and quality of life variables in the total sample and on both dialysis modalities
Variables Possible range
Total sample (N= 61)
Mean (SD) Range
HD (N= 30)
Mean (SD) Range
PD (N= 31)
Mean (SD) Range
Statistic p
Facilitators of adherence to treatment 
Treatment information
Relation with healthcare team
Family support
Knowledge of medication
Do you self-administer the medication?
Benefi ts of medication
Knowledge about diet
Benefi ts of diet
Do you follow the nephrologist’s instructions?
Perceived effort
Perceived capacity
Global score (GS) (0-43)* 
BP Morisky-Green-Levine Test¹
Do you ever forget to take the antihypertensive drugs? 
Are you careless about the schedules?
If you feel good, do you stop taking the antihypertensive drugs?
If you feel bad, do you stop taking the antihypertensive drugs?
Score**
HP Morisky-Green-Levine Test²
Do you ever forget to take the phosphate binders? 
Are you careless about the schedules?
If you feel good, do you stop taking the phosphate binders?
If you have side-effects, do you stop taking the phosphate binders?
Score**
Psychological variables
BDI-II
STAI-S
PSS-10
Standardized SF-36 v2 subscales
Physical Function 
Physical Role 
Bodily Pain 
General Health 
Vitality 
Social Function 
Emotional Role 
Mental Health 
PCS
MCS
1 (not at all) - 5 (very much)
1 bad to 5 good
1 bad to 5 good
0 no – 1 yes
0 no – 1 yes
1 none to 5 many
0 no – 1 yes
1 none to 5 many
5 (100%) to 1 (0%)
1 much 5 not at all
1 much 5 not at all
Min 0 – Max 43
0 No – 1 Yes
0 No – 1 Yes
0 No – 1 Yes
0 No – 1 Yes
0 No – 1,2,3,4, Yes
0 No – 1 Yes
0 No – 1 Yes
0 No – 1 Yes
0 No – 1 Yes
0 No – 1,2,3,4, Yes
0-63
0-60
0-40
0-100
0-100
0-100
0-100
0-100
0-100
0-100
0-100
0-100
0-100
3.28 (1.40) 1-5
4.34 (0.94) 1-5
4.44 (1.16) 1-5
0.72 (0.45) 0-1
0.85 (0.35) 0-1
3.97 (0.78) 2-5
0-82 (0.38) 0-1
3.72 (0.83) 2-5
4.24 (0.69) 2-5
4.33 (0.98) 1-5
1.45 (0.69) 1-4
32.06 (3.25) 24-38 
 (%) Yes / No
50.0 / 50.0
57.5 / 42.5
2.5 / 97.5
22.5 / 77.5
15.0 / 85.0
43.5 / 56.5
50.0 / 50.0
2.2 / 97.8
21.3 / 78.9
21.7 / 78.3
12.78 (9.67) 0-44
18.31 (12.60) 3-56
14.28 (8.18) 2-38
58.75 (27.16) 5-100
54.48 (34.39) 0-100
32.00 (30.52) 0-90
49.30 (12.87) 30-100
56.04 (11.95) 31-87
46.49 (13.10) 12-75
80.97 (29.64) 0-100
58.81 (12.91) 20-80
58.33 (8.73) 37-76
48.18 (5.92) 31-57
2.43 (1.33) 1-5
3.93 (1.10) 1-5
4.27 (1.38) 1-5
0.67 (0.47) 0-1
0.83 (0.37) 0-1
3.87 (0.77) 3-5
1 (0.00) 1-1
3.67 (0.88) 2-5
4.27 (0.69) 2-5
4.40 (0.96) 1-5
1.57 (0.77) 1-4
30.90 (3.02) 24-38
 (%) Yes / No
45.5 / 54.4
72.7 / 27.3
9.1 / 90.9
27.3 / 72.7
9.1 / 90.9
68.4 / 31.6
42.1 / 57.9
5.3 / 94.7
21.1 / 78.9
31.6 / 68.4
14.50 (10.37) 0-44
18.40 (12.59) 4-56
15.43 (8.66) 3-38
48.50 (26.95) 5-95
46.25 (31.17) 0-100
54.40 (37.13) 0-100
36.37 (17.62) 5-85
44.82 (22.47) 0-81
64.22 (28.48) 12-100
73.56 (33.78) 0-100
65.51 (21.47) 20-95
34.30 (8.66) 21-52
47.11 (10.71) 27-62
4.10 (0.90) 2-5
4.74 (0.57) 3-5
4.61 (0.88) 1-5
0.77 (0.42) 0-1
0.87 (0.34) 0-1
4.07 (0.79) 3-5
0.65 (0.48) 0-1
3.77 (0.80) 2-5
4.23 (0.71) 3-2
4.27 (1.01) 2-5
1.33 (0.60) 1-3
33.27 (3.09) 25-38
(%) Yes / No
51.7 / 48.3
51.7 / 48.3
0.0 / 100.0
20.7 / 79.3
17.2 / 82.8
51.9 / 48.1
55.6 / 44.4
0.0 / 100.0
22.2 / 77.8
14.8 / 85.2
11.07 (8.76) 0-44
18.21 (12.84) 3-55
13.13 (7.64) 2-33
69.00 (23.61) 5-100
62.71 (36.98) 0-100
76.60 (27.36) 0-100
34.82 (17.71) 5-75
51.11 (26.79) 0-100
70.08 (29.13) 0-100
87.79 (24.37) 8-100
74.28 (19.03) 20-100
39.42 (8.67) 13-52
49.83 (11.50) 19-62
U= 153.50
U= 239.00
U= 423.00
χ²= 0.877
χ²= 0.172 
U= 378.50
χ²= 12.98
U= 425.00
U= 448.50
U= 421.00
U= 375.00
t= -3.00
χ²= 0.125
χ²= 1.440
χ²= 0.270
χ²= 0.198
χ²= 0.416
χ²= 1.865
χ²= 0.807
χ²= 1.453
χ²= 0.009
χ²= 1.842
t= 1.38
t= 0.06
t= 0.96
t= -2.80
t= -1.88
t= -2.34
t= 0.33
t= -0.96
t= -0.77
t= -1.83
t= -1.63
t= -2.23
t= -0.93
.000
.000
.432
.349
.679
.360
.000
.539
.792
.634
.187
.004
.723
.230
.100
.656
.519
.172
.369
.228
.925
.175
.171
.954
.348
.007
.074
.023
.741
.341
.446
.073
.109
.030
.361
Note: HD= hemodialysis, PD= peritoneal dialysis *= higher score indicates greater degree of treatment adherence, BP= hypertension,** Nonadherent with only one positive response¹= (N= 
17HD, N= 27PD), HP= hyperphosphoremia, ²= (N= 25HD, N= 26PD), PCS= physical component summary, MCS= mental component summary
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compliant and noncompliant patients either in the psychological 
variables or in HRQOL. See Table 4.
Associations between indicators of adherence, psychological 
variables, and HRQOL
 
In order to study in depth the relations between indicators of 
adherence to treatment, psychological variables, and HRQOL, 
we performed a correlational analysis with the total sample. 
Beforehand, we assessed the associations between the variables 
separately in each dialysis group, obtaining no data of interest for 
this study. We therefore decided to analyze the sample as a whole. 
The correlations are presented in Table 5. 
After determining the relations between the variables, we 
decided to appraise the relative weight of the variables on the PCS 
and MCS of the HRQOL. For this purpose, we performed multiple 
linear regression analysis for each outcome variable. We entered 
the variables that were previously associated with the physical and 
Table 3
Effect of depression (BDI-II) on the facilitators of adherence and indicators of quality of life of the 61 patients on dialysis
Variables
No depression (N= 47)
Mean (SD) Range
Depression (N= 14)
Mean (SD) Range
U Statistic p
Facilitators of adherence to treatment (GS)*
Standardized SF-36 v2 subscales
Physical Function 
Physical Role 
Bodily Pain 
General Health 
Vitality 
Social Function 
Emotional Role 
Mental Health 
PCS
MCS
32.80 (2.85) 25-38
62.80 (25.46) 5-100
61.50 (33.04) 0-100
31.80 (29.79) 0-90
69.90 (12.32) 45-100
54.70 (10.62) 31-81
44.90 (12.05) 13-62
89.30 (23.34) 0-100
61.10 (11.61) 20-80
60.40 (7.81) 43-76
49.40 (4.79) 36-57
30.10 (3.67) 24-37
42.90 (26.36) 5-75
30.40 (28.99) 0-93
35.00 (33.68) 0-90
69.30 (13.71) 30-85
60.30 (15.43) 38-87
50.00 (15.50) 25-75
53.00 (32.13) 0-100
51.40 (14.86) 20-75
51.80 (8.63) 37-66
44.30 (7.52) 31.54
166.50
186.00
145.50
305.00
290.00
256.00
242.00
92.00
181.00
133.50
174.00
.010
.021
.002
.855
.939
.335
.289
.000
.020
.002
.023
Note: *= higher score indicates higher degree of adherence to treatments, PCS= physical component summary, MCS= mental component summary
Table 4
 Relations between indicators of specifi c adherence to antihypertensive drugs (N= 44) and phosphate binders (N= 51) with quality of life in the total sample of patients on 
dialysis
Variables
BP Morisky-Green-Levine Test 
Mean (SD) Range U Statistic p
Adherence (N= 7) Nonadherence (N= 37)
Standardized SF-36 v2 subscales
Physical Function 
Physical Role 
Bodily Pain 
General Health 
Vitality 
Social Function 
Emotional Role 
Mental Health 
PCS
MCS
80.00 (14.14) 65-100
89.58 (10.20) 75-100
25.00 (35.07) 0-90
62.50 (12.94) 45-80
58.33 (7.56) 50-68
52.08 (9.40) 37-62
95.83 (10.20) 75-100
60.83 (4.91) 55-70
66.33 (5.31) 61-76
51.16 (1.72) 49-53
63.03 (25.21) 5-100
52.46 (33.83) 0-100
28.48 (27.39) 0-90
70.16 (13.80) 30-100
53.71 (9.76) 37-81
46.25 (11.44) 12-75
81.56 (29.07) 8-100
56.87 (14.46) 20-80
58.53 (8.55) 43-74
47.43 (6.22) 33-57
58.50
38.50
87.50
60.00
64.00
62.00
69.50
95.00
43.00
56.00
.114
.018
.646
.198
.183
.195
.197
.967
.046
.147
HP Morisky-Green-Levine Test 
Adherence (N= 11) Nonadherence (N= 40)
Standardized SF-36 v2 subscales
Physical Function
Physical Role
Bodily Pain
General Health
Vitality
Social Function
Emotional Role
Mental Health
PCS
MCS
64.50 (25.86) 15-95
68.12 (31.38) 0-100
33.00 (37.13) 0-90
67.50 (12.07) 50-90
55.00 (7.68) 43-68
47.50 (11.48) 25-62
88.33 (31.47) 0-100
64.00 (8.43) 55-80
61.60 (8.04) 50-76
50.00 (4.59) 38-54
64.14 (22.83) 20-100
55.35 (34.27) 0-100
28.57 (26.47) 0-80
70.78 (12.64) 45-100
54.04 (10.86) 31-81
47.65 (13.25) 12-75
84.28 (26.94) 8-100
60.00 (13.14) 20-80
59.43 (7.57) 47-74
48.62 (5.44) 36-57
172.50
137.00
171.00
131.50
158.50
159.00
145.50
153.00
136.50
130.00
.945
.296
.911
.395
.738
.975
.346
.626
.487
.373
Note: BP= hypertension, HP= hyperphosphoremia, PCS= physical component summary, MCS= mental component summary
Helena García-Llana, Eduardo Remor and Rafael Selgas
84
mental health components in the regression model (Table 5; the 
results of the sociodemographic and clinical variables were omitted 
to save space). Thus, the regression model for the variable PCS (F= 
8.699, p= .000) accounted for 30% of the variance in the outcome 
variable (R²c= 0.30), explained by the variables work (yes / no) 
(B= 6.478, SE= 2.56, β= .319, t= 2.525, p= .015), depression (B= 
-0.254, SE= 0.110, β= -.263, t= -2.129, p= .038), and gender (male 
/ female) (B= -4.641, SE= 2.19, β= -.251, t= -2.120, p= .039). For 
the MCS (R²c= .23, F= 16.632, p= .000), 23% of variance was 
accounted for a single variable: depression (B= -0.298, SE= 0.73, 
β= -.489, t= -4.078, p= .000). The remaining variables were not 
entered in the model.
Discussion
The present study yields some original and interesting results 
to further our understanding of the relation between therapeutic 
adherence, psychological processes, and the experience of disease 
in patients on dialysis. 
For example, this study reveals a lack of specifi c adherence to 
phosphate binders in 72.9% of patients on hemodialysis and in 
85.2% of patients in peritoneal dialysis. The reports on adherence 
diffi culties to treatment in chronic disease patients can be found 
in several studies (Cvengros et al., 2004; Reach, 2008; Remor, 
2011). However, there are few that specifi cally address the topic 
of adherence to hyperphosphoremia treatment and their data 
vary between 22 and 74%, according to authors (Arenas, Malek, 
Moledous, Álvarez-Ude, & Reig-Ferrer, 2010; Karamanidou, 
Clatworthy, Weinman, & Horne, 2008). Our data support the 
literature that describes high rates of non-adherence in this 
sphere. 
In our study, patients on peritoneal dialysis present a higher 
educational level, they have more information about the treatments, 
a better relationship with their healthcare team, and greater self-
reported adherence. In line with this, a review of the literature on 
adherence to treatment in dialysis (Maldaner, Beuter, Brondani, 
Budó, & Pauletto, 2008) identifi ed nine factors that affect adherence, 
underlining the relationship with the healthcare team, information, 
and high educational level. As it is a self-administered technique, 
peritoneal dialysis draws patients nearer to their assistential team, 
and it implies that patients are well informed and perceive the 
team’s accessibility. 
The relation between information and adherence to treatment 
in nephrology is still controversial. In this sense, our hemodialysis 
patients reported having more information about diet than patients 
on peritoneal dialysis, and this makes sense because any dietary 
transgression can be a life threatening emergency for a patient on 
hemodialysis. However, and coinciding with our results, Durose, 
Holdsworth, Watson, and Przygrodzka (2004), have observed 
that patients on hemodialysis who had greater dietary knowledge 
on phosphorus control were also the patients who displayed the 
least adherence. We could thus state that although information is 
necessary it is not enough to change adherence behavior. 
No signifi cant differences were found in the psychological 
variables between the two dialysis modalities, although the mean 
scores in depression, anxiety, and stress were lower in patients on 
dialysis compared with the reference population (i.e., [PSS-10] 
Remor, 2006; [BDI-II] Sanz et al., 2003; [STAI] Seisdedos, 1982). 
In contrast, differences in HRQOL that favored peritoneal 
dialysis patients were found in the Physical Function and Bodily 
Pain subscales and in the PCS. Along the same lines, Rodríguez-
Fructuoso et al., (2011) also found that patients on peritoneal 
Table 5 
Correlation coeffi cients between variables of adherence to treatment, psychological variables, and HRQOL in 61 patients on dialysis
Adherence to treatment Psychological variables HRQOL (MOS-SF-36)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1. Adherence to treatment (GS)¹ 
2. BP Morisky Test .204*
3. HP Morisky Test .245* .829**
4. BDI-II -.376** -.154 -.091
5. STAI-S -.120* -.110 -.121 .586**
6. PSS-10 -.295* -.024 -.080 .767** .477**
7. Physical Function .275* .257 .010 -.400** -.083 -.337*
8. Physical Role .204 .384* .158 -.443** -.298* -.349** .528** .
9. Bodily Pain .177 .074 .017 -.298* -.038 -.275* .261* 363**
10. General Health .060 .218 .133 -.384** -.281* -.249 .351** .249* .319*
11. Vitality .200 .219 .051 -.572** -.438** -.416** .459** .662** .496** .532**
12. Social Function .132 .219 .005 -.435** .444** -359** .263* .533** .411** .303* .599**
13. Emotional Role .346** .209 .142 -.533** -.265* -359** .320* .558** .397** .224 .624** .471**
14. Mental Health .261* .007 .074 -.687** -.462** -.632** .296* .483** .480** .480** .624** .411** .621**
15. PCS .168 .338* .109 -.329* -.056 -.266* .798** .668** .615** .615** .595** .447** .235 .278*
16. MCS .257 .245 .139 -.640** -.525** -.509** .128 .490** .392** .392** .720** .662** .840** .828** .133
Note: ¹= survey of treatment adherence facilitators (GS 0-43), BP Morisky Test= Morisky-Green-Levine Test for specifi c adherence to antihypertensive drugs, HP Morisky Test= Morisky-Green-
Levine Test for specifi c adherence to phosphate binders, PCS= physical component summary, MCS= mental component summary
* p<.05; ** p<.01
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dialysis presented better HRQOL scores in the Physical Function 
and Bodily Pain subscales than patients on hemodialysis. In a 
systematic review of the impact of the two dialysis modalities 
on HRQOL, it is concluded that patients on peritoneal dialysis 
report higher scores in its physical health components, but that 
there are no observed differences its mental health ones (Boateng 
& East, 2011). The same pattern is observed in the results of this 
study. Due to the aggressiveness of the technique, the patients 
on hemodialysis present an important symptomatological burden 
(i.e., pruritus, cramps, and nausea) that can interfere with their 
HRQOL. In contrast, patients on peritoneal dialysis usually have 
greater symptomatological control, although they sometimes 
present episodic complications derived from the technique (i.e., 
peritonitis). In any case, patients on peritoneal dialysis were 
younger and presented less comorbidity, which could explain 
higher HRQOL. In spite of this, the relation between quality of 
life and dialysis modality is still confusing. Other comparative 
studies carried out in Spain (Ruiz de Alegría et al., 2009) show 
no HRQOL advantage associated with peritoneal dialysis. The 
HRQOL scores observed in this study are lower than those of the 
reference population (Alonso et al., 1998).
Another noteworthy aspect is that, in our study, the variables 
depression, anxiety, and stress were negatively associated with the 
adherence facilitators to treatment, thus indicating that negative 
emotional states could be a risk to therapeutic compliance. These 
results corroborate those described by Cukor, Rosenthal, Jindal, 
Brown, and Kimmel (2009). Moreover, these negative emotional 
states can negatively affect diverse domains of HRQOL and its two 
summaries components. These results have also been described by 
Walters, Hays, Spritzer, Fridman, and Carter (2002). It is important 
to remember, specifi cally with regard to the BDI-II results, that 
its use in population with chronic health problems should be 
interpreted with precaution because it is diffi cult to ensure that the 
patient’s answers to items on energy, appetite, and sleep included 
in the questionnaire are not affected by the experience of the 
disease.
Upon analyzing in the total sample the relation between specifi c 
adherence to antihypertensive drugs and phosphate binders 
and the psychological and HRQOL variables, it was found that 
patients who reported compliance with the prescribed schedule of 
antihypertensive drugs presented a better HRQL in the Physical 
Role subscale and in the PCS. 
The data reported herein indicate the complexity of factors 
that can affect perceived quality of life. We have observed that 
situational (occupational), gender, and psychological state 
characteristics partially explain HRQOL. Other authors (i.e., 
Morales-Jaimes, Salazar-Martínez, Flores-Villegas, Bochicchio-
Ricardelli, & López-Caudana, 2008; Varela, Vázquez, Bolaños, & 
Alonso, 2011) have described similar results. 
As a limitation of this study, we mention the small size of the 
sample, although this is the fi rst study of its kind in Spain that has 
assessed more than 50% of dialysis patients treated in a medical 
unit. 
To conclude, the results of this study point out the diffi culties 
experienced by patients to adhere to oral medication in both 
dialysis modalities, and the role that negative emotional states, 
especially depression, can play in the quality of life of kidney 
patients. Therefore, early detection and intervention in these 
potential factors of HRQOL deterioration may help improve 
the physical and mental health status of chronic renal failure 
patients.
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